Business · 19/12/2017
FDA Announces Public Workshop on Generic Orally Inhaled and Nasal Drug Products
The FDA is hosting a public workshop to discuss new insights on product development and bioequivalence assessments for generic OINDPs, seeking input on analytical methods and procedures for ANDA submissions.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →